Elodie Plan, Ph.D., MBA

Chief Business Development Officer & Deputy CEO

Portrait-of-Elodie-Plan_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, serving as Chief Business Development Officer, part of the executive leadership team
  • Expertise includes model informed drug development, pharmacometrics (especially count data models, Markov models, and item response theory models), and trial design in therapeutic areas such as neurosciences, women’s health, and immunology
  • Previously worked as Researcher at Uppsala University, Sweden, where she co-supervised Postdoctoral Researchers, and Visiting Scientist at Metrum Research Group, USA
  • M.Sc. in Biostatistics (2006) from University Paris Diderot, France, Pharm.D. (2007) from University of Poitiers, France; Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden, and MBA (2024) from Stockholm School of Economics, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357 treatmentA disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo scoreTraining the next generation of pharmacometric modelers: a multisector perspectiveBounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 730357Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response ModellingModel Based Support to Biosimilarity Assessment Planning – A Case Study of PegfilgrastimSensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity StudiesAssessment of Expected Drug Exposure Relative Maximum Safety Limits in Early Phase StudiesA Population Pharmacokinetic-Pharmacodynamic Model of PegfilgrastimDosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial DataModel Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics